

# Ninth meeting of the Working Group on Monitoring of Neglected Tropical Diseases Drug Efficacy

Geneva, 12 March 2020





# Ninth meeting of the Working Group on Monitoring of Neglected Tropical Diseases Drug Efficacy

Geneva, 12 March 2020



Ninth meeting of the Working Group on Monitoring of Neglected Tropical Diseases Drug Efficacy, Geneva, 12 March 2020

ISBN 978-92-4-001408-4 (electronic version)

ISBN 978-92-4-001409-1 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Ninth meeting of the Working Group on Monitoring of Neglected Tropical Diseases Drug Efficacy, Geneva, 12 March 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

# Contents

---

<b>1 Background</b>	<b>1</b>
<b>2 Drug efficacy studies</b>	<b>4</b>
2.1 Benzimidazoles	4
2.2 Praziquantel	5
2.3 Discussion	5
2.4 Action and next steps	5
<b>3. Research update on praziquantel efficacy</b>	<b>6</b>
3.1 Discussion	7
<b>4. Updates on drug development</b>	<b>8</b>
<b>5. Manual on assessing anthelmintic drug efficacy</b>	<b>9</b>
5.1 Action and next steps	9
<b>6. Establishing a network of NTD laboratories</b>	<b>10</b>
6.1 Discussion	10
<b>7. Role of the WHO Working Group on Drug Efficacy</b>	<b>11</b>
References	12
Annex 1. List of participants	13
Annex 2. Agenda	15



# 1. Background

---

The World Health Organization (WHO) recommends preventive chemotherapy as a public health strategy to control and prevent morbidity due to four helminth infections (lymphatic filariasis, onchocerciasis, schistosomiasis and soil-transmitted helminthiases) and one chlamydial infection (trachoma). In 2018, global coverage of preventive chemotherapy reached 64% in endemic populations, with more than 1.1 billion individuals treated (1). With such a relatively large drug pressure, and one which will be continued over the next few years on the road towards elimination of neglected tropical diseases (NTDs), the potential risk of emerging resistance must be considered.

The Working Group on Monitoring of Neglected Tropical Diseases Drug Efficacy has developed a protocol to guide assessments of drug efficacy against both schistosomiasis (with praziquantel) and soil-transmitted helminthiases (with albendazole and mebendazole). It also recommends testing drug combinations and co-administering albendazole and mebendazole with ivermectin to contain the risk of emergence of resistance. Assessments are recommended in particular in areas where preventive chemotherapy programmes have attained a high coverage for more than 5 years. To date, more than 20 drug efficacy trials have been performed in 15 countries (Table 1). While in most countries no signs of resistance to praziquantel have been observed, in others reduced efficacy has been noted. For example, the mean *Schistosoma mansoni* egg reduction rate in schoolchildren in Uganda who had received 8 or 9 previous rounds of preventive chemotherapy was found to be significantly lower than the mean reduction rate in schoolchildren who had received 5 or a lower number of rounds of preventive chemotherapy (2). Similarly, in some countries, doubtful efficacy results have been reported for mebendazole against hookworm infections.

The objectives of the meeting were:

- to evaluate the reports of drug efficacy trials conducted in endemic countries during 2019;
- to discuss research updates in the area of anthelmintic resistance;
- to propose an update for the WHO manual on assessing anthelmintic drug efficacy; and
- to discuss the first draft of a document on establishing a network of laboratories to support periodic evaluation of anthelmintic efficacy in endemic countries.

The two-day meeting was condensed into one day due to the COVID-19 pandemic. Although several participants returned urgently to their home countries before the start of the meeting, many participated online. The list of participants is attached as Annex 1 and the agenda as Annex 2.

Table 1. Drug efficacy trials conducted under the supervision of the Working Group on Drug Efficacy, 2010–2019

Country	Year	Drug	Target	Egg reduction rate (%)	95% confidence interval	Drug efficacy classification	Reference
SOIL-TRANSMITTED HELMINTHIASES							
Brazil	2010	ALB	<i>A. lumbricoides</i>	100.0	NR	Satisfactory	(3)
			Hookworm	97.5	NR	Satisfactory	(3)
Cambodia	2010	ALB	Hookworm	97.6	NR	Satisfactory	(3)
Cameroon	2010	ALB	<i>A. lumbricoides</i>	99.2	NR	Satisfactory	(3)
			<i>T. trichiura</i>	39.2	NR	Reduced	(3)
			Hookworm	93.0	NR	Satisfactory	(3)
Ethiopia	2010	ALB	<i>A. lumbricoides</i>	100.0	NR	Satisfactory	(3)
			<i>T. trichiura</i>	92.4	NR	Satisfactory	(3)
			Hookworm	99.7	NR	Satisfactory	(3)
India	2010	ALB	Hookworm	87.1	NR	Doubtful	(3)
United Republic of Tanzania (Zanzibar)	2010	ALB	<i>A. lumbricoides</i>	100.0	NR	Satisfactory	(3)
			<i>T. trichiura</i>	52.0	NR	Satisfactory	(3)
			Hookworm	95.3	NR	Satisfactory	(3)
Viet Nam	2010	ALB	<i>A. lumbricoides</i>	100.0	NR	Satisfactory	(3)
			<i>T. trichiura</i>	92.3	NR	Satisfactory	(3)
			Hookworm	100.0	NR	Satisfactory	(3)
Brazil	2013	MEB	<i>A. lumbricoides</i>	97.5	95.7–99.3	Satisfactory	(4)
			Hookworm	84.4	80.9–87.9	Satisfactory	(4)
Cameroon	2013	MEB	<i>A. lumbricoides</i>	99.8	99.5–100.0	Satisfactory	(4)
			<i>T. trichiura</i>	56.2	39.4–73.0	Satisfactory	(4)
			Hookworm	71.9	55.6–88.1	Satisfactory	(4)
Cambodia	2013	MEB	Hookworm	79.7	73.7–85.7	Satisfactory	(4)
Ethiopia	2013	MEB	<i>A. lumbricoides</i>	98.6	97.7–99.4	Satisfactory	(4)
			<i>T. trichiura</i>	65.9	57.5–74.4	Satisfactory	(4)
			Hookworm	65.4	55.3–75.6	Doubtful	(4)
United Republic of Tanzania (Zanzibar)	2013	MEB	<i>A. lumbricoides</i>	97.1	95.1–99.0	Satisfactory	(4)
			<i>T. trichiura</i>	51.2	41.3–61.0	Satisfactory	(4)
			Hookworm	74.6	63.8–85.4	Satisfactory	(4)
Viet Nam	2013	MEB	<i>A. lumbricoides</i>	93.9	91.2–96.5	Satisfactory	(4)
			<i>T. trichiura</i>	76.8	67.7–85.8	Satisfactory	(4)
			Hookworm	95.0	91.2–98.9	Satisfactory	(4)
Ethiopia	2016	ALB	<i>A. lumbricoides</i>	99.9	99.8–100	Satisfactory	(5)

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_24174](https://www.yunbaogao.cn/report/index/report?reportId=5_24174)



云报告  
https://www.yunbaogao.cn

云报告  
https://www.yunbaogao.cn

云报告  
https://www.yunbaogao.cn